Extension of the postponement of the settlement of Vifor Pharma tender offer

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Limited (ASX: CSL; USOTC:CSLLY) today announced an update regardin

7월 13일 16:45

Update on the timeline for Vifor Pharma tender offer

Regulatory News: CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL

5월 13일 10:00

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202204

4월 28일 15:30

94th Vifor Pharma Group Annual General Meeting

Regulatory News: At today’s 94th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put f

4월 27일 17:25

DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma today announced full results from its phase-IIIb DIAMOND

4월 4일 14:10

Publication of definitive end result for Vifor Pharma tender offer

CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY),

3월 28일 15:00

Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202203

3월 23일 16:40

Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of globa

3월 8일 17:05

Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of globa

3월 3일 17:30

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202202

2월 28일 15:40

Vifor Pharma appoints two new members to the Executive Committee

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced the appointment of acting Chief Fin

2월 3일 09:35

VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis

Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European Commission has approved Tavn

1월 20일 10:00

Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma today announced positive findings in the completed phase-

2021년 12월 21일 17:30

Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and its partner American Regent, Inc., a Daiichi Sa

2021년 12월 20일 15:40

Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced the divestment of its finished drug

2021년 12월 16일 15:30

CSL Limited announces tender offer to acquire Vifor Pharma Ltd

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vi

2021년 12월 14일 17:05

Vifor Pharma comments on media speculation

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor is in discussions with CSL about a possible transaction. No deci

2021년 12월 13일 17:31

First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease

Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evalu

2021년 12월 13일 14:35

Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced the appointment of Hervé Gisserot a

2021년 12월 10일 16:25

Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced

2021년 12월 10일 16:20

Vifor Pharma comments on market speculations

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Due to current market speculations, Vifor Pharma Group states the foll

2021년 12월 3일 11:50

Vifor Pharma announces changes to the Executive Committee as CFO retires

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced that Colin Bond, Chief Financial Of

2021년 11월 30일 15:36

Vifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosis

Already for the seventh consecutive year of Iron Deficiency Day, Vifor Pharma is supporting a growing international alliance inclu

2021년 11월 26일 15:30

Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a

2021년 11월 22일 15:50

VFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitis

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced tha

2021년 11월 12일 15:35

페이지당 25개

페이지당 5개페이지당 10개페이지당 25개페이지당 50개페이지당 75개페이지당 100개